NIH Awards Marker Therapeutics $2M for Clinical Investigation in Relapsed Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics, Inc. (NASDAQ:MRKR) has been awarded a $2 million grant from the NIH SBIR program to support the clinical investigation of MT-601 in relapsed non-Hodgkin's lymphoma patients. This funding will aid the Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601.
August 12, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marker Therapeutics has been awarded a $2 million NIH grant to support the clinical investigation of MT-601 in relapsed non-Hodgkin's lymphoma patients. This funding will support the Phase 1 APOLLO study, which evaluates the safety and efficacy of MT-601.
The $2 million NIH grant is a significant non-dilutive funding source that will support the clinical investigation of MT-601, potentially leading to positive clinical outcomes and future revenue streams. This news is likely to boost investor confidence and positively impact MRKR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100